a The First Department of Internal Medicine , University of Occupational and Environmental Health , Kitakyushu, Fukuoka , Japan.
Expert Rev Clin Immunol. 2019 Jul;15(7):693-700. doi: 10.1080/1744666X.2019.1608821. Epub 2019 Apr 25.
: JAK, which constitutively binds to some cytokine receptors, plays an important role in cytokine signaling. While JAK is comprised of JAK1, JAK2, JAK3, and Tyk2, more than 40 types of cytokines transmit signals through JAK. Baricitinib is reported to be highly effective in the treatment of rheumatoid arthritis (RA) and is the second drug launched as a JAK inhibitor for RA. : We provide an overview of the mechanisms of action of baricitinib and its clinical implications in RA and other autoimmune diseases based on recent reports. This review outlines the mechanisms of action of baricitinib on human immune cells, the results of Phase III trials for RA, and the results of Phase II trials on SLE. : Baricitinib has potential to fine-tune various immune networks through a variety of mechanisms. Precision medicine is required in order to achieve maximum effects of targeted synthetic DMARDs including baricitinib and biological DMARDs in the future.
JAK 与某些细胞因子受体持续结合，在细胞因子信号转导中发挥重要作用。JAK 由 JAK1、JAK2、JAK3 和 Tyk2 组成，超过 40 种细胞因子通过 JAK 传递信号。巴瑞替尼被报道在治疗类风湿关节炎（RA）方面非常有效，是作为 RA 的 JAK 抑制剂推出的第二种药物。
我们根据最近的报告，提供了巴瑞替尼在 RA 和其他自身免疫性疾病中的作用机制及其临床意义的概述。本综述概述了巴瑞替尼对人类免疫细胞的作用机制、RA 的 III 期试验结果以及 SLE 的 II 期试验结果。
巴瑞替尼通过多种机制有潜力精细调节各种免疫网络。为了在未来实现包括巴瑞替尼在内的靶向合成 DMARDs 和生物 DMARDs 的最大效果，需要精准医学。
